Home > Journals > Panminerva Medica > Past Issues > Panminerva Medica 2015 March;57(1) > Panminerva Medica 2015 March;57(1):1-13

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions
Cite this article as
Share

 

  TARGETING CARDIAC ISSUES 

Panminerva Medica 2015 March;57(1):1-13

Copyright © 2015 EDIZIONI MINERVA MEDICA

language: English

Bioresorbable scaffolds: focus on vascular response and long-term safety

Scalone G., Brugaletta S., Gomez O., Otsuki S., Sabate M.

Thorax Institute, Department of Cardiology, IDIBAPS: Institut d’Investigacions Biomediques Agust Pi i Sunyer (IDIBAPS), Hospital Clinic, Barcelona, Spain


PDF


Bioresorbable vascular scaffolds (BVS) are considered the fourth revolution in Interventional Cardiology, thus promising to address some of the pending issues with current-generation drug eluting stents (DES). Notably, most of the potential advantages of BVS over other current devices are due to a peculiar vascular response, called “vascular restoration therapy”. The emerging data from real-world expanded use registries suggest that BVS use is feasible in a wide variety of patients (from low- to high- risk), and lesions (from simplex to complex). However, few safety concerns with currently available BVS have arised from initial experiences all over the word. Data from ongoing large-scale randomized controlled trials will be able to demonstrate whether BVS improve patient early and long-term outcomes compared to best-in-class DES.

top of page